

Phylogica

Investor Presentation

May 2018

Disclaimer

The purpose of the presentation is to provide an update of the business of Phylogica Limited (ASX:PYC) ['Phylogica']. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Phylogica and should not be relied upon as an independent source of information. Please contact Phylogica and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Phylogica's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Phylogica's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Phylogica. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.



The problem – the ‘undruggable target’

PHYLOGICA



1

The highest value drug targets exist **inside cells**

+

Drug

2

The cell membrane is specifically **designed to keep ‘foreign’ substances out**

=

3

Drugs are **unable to reach the 80% of targets** that reside inside cells

The insight: in 1988, it was discovered that HIV was able to cross the cell membrane and that this ability was driven by a fragment of its genome called ‘Tat’

Phylogica's solution – leverage nature

Build a unique drug library with 500 billion peptides

- Our core patent underpins our drug library based on the genomes of viruses, bacteria and other organisms
- We cut the genome of each organism into fragments to create a library of 500 billion peptides

Screen for the rare peptides that can cross the cell wall

- Evolutionary pressures on these peptides over millions of years have enriched them for drug like properties
- Specifically, many viruses are known to have the ability to cross the cell wall
- We leverage nature's solution by screening our libraries for rare peptides with the ability to cross the cell wall

Use peptides to 'tow' a drug cargo across the cell wall

- Join the peptide with the ability to cross the cell wall to a drug 'cargo' to form a peptide-drug conjugate



Validation of platform across multiple contexts, including in animal studies

PHYLOGICA

Concept

Cell penetrating peptide

+ Drug cargo

= Drug conjugate

Disease model

- Duchenne Muscular Dystrophy
- Breast Cancer
- Melanoma

Outcome

Muscle-cell successfully treated by FPP-cargo



Breast cancer inhibited by FPP-cargo through intracellular target



FPP-cargo treatment increased survival time by 100%



Note: FPP = Functional Penetrating Peptide

What's new in 2018?

	Drug libraries	Screening tools	Analytics capability	In vivo outcomes
2017				
	36% of phyla represented – not specifically designed for FPPs	Manual – low throughput	Insufficient data to use advanced analytics	Very encouraging – clear point of differentiation
2018				**Coming soon…**
	93% of phyla represented – specifically enriched for FPPs	Automated – high throughput	Advanced analytics enabled – move from observational to predictive power	

Note: FPP = Functional Penetrating Peptide

Near term milestones

	3Q2018	4Q2018
Delivery Platform	★ Systemic delivery of Cre in vivo	
Cancer vaccine	★ T-cell expansion in vivo	
CRISPR		★ Delivery of Cas9 ex vivo
Target Product Profile		★ Evaluation of PK extension in vivo

Investment highlights



- Platform addresses a **large unmet need** – 80% of drug targets exist inside the cell
- Phylogica's proprietary platform provides Pharma customers **the solution** to getting a working cargo inside cells
- The platform has been **validated in animals** – the transition from 'proof of concept' to therapeutics has begun
- Management team with both **commercial and technical** capabilities
- Scientific Advisory Board drawn from **leading global figures** in the field (Harvard, Nektar Therapeutics, NYU)
- Operations have just **reached scale with a 100-fold expansion** in throughput in 2018 – **technical milestones are near**